the 503A question that gets asked weekly, answered properly
Posting this as a discussion rather than a claim: the 503A question that gets asked weekly, answered properly.
Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.
A beyond-use date derived from published stability data means something different from one assigned by default rule. Asking which is a fair question and the answer is usually available.
The shortage list is the legal hinge: the permissions that allow certain compounding to happen at scale are tied to a drug’s shortage status, which changes.
Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.
best — the order this archive was captured in
Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.
the pharmacy and the prescriber are two separate questions
What did the intake actually ask you?
Yes — asking which facility, by name, is the single most useful question and most clinics will answer it.
the label on a compounded vial is a legal document, read it
Kept the label from every vial. When the shortage status changed, having the paper trail made the conversation much shorter.
Compounded preparations are not approved products and carry no bioequivalence claim.
bruno_dumitru is right about the concentration trap. It breaks arithmetic that has been reliable for months.
What is the beyond-use date and what is it based on?
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Paid noticeably more at one clinic than another for what turned out to be the same facility behind both.
Adding one thing — ask for the facility name. Most will give it, and the ones that will not have answered you.
[deleted]
salt forms are the recurring argument and the answer is boring
That is not what patient-specific means. It refers to the prescription, not to a customisation of the formula.
a telehealth intake that asks nothing has told you what it is
Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.
Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.
ask what the beyond-use date is based on
Cosigning the beyond-use date question. What it is based on tells you whether anybody has done stability work.
Removed the staff name. Facilities and clinics can be named here; individuals cannot.
the API source is the question nobody asks and everybody should
do not assume the concentration matches the branded product
Nothing in this thread is medical advice, and the choice between arrangements is one for you and a prescriber who knows your history.
- 1Paid noticeably more at one clinic than another for what turned out to be…10 comments in this branch · started by u/tobias_vukovic
- 2Compounded preparations are not approved products and carry no…9 comments in this branch · started by u/bruno_dumitru